213 related articles for article (PubMed ID: 24129677)
1. Clinical course of patients with Behçet's uveitis following discontinuation of infliximab therapy.
Kawaguchi T; Kawazoe Y; Kamoi K; Miyanaga M; Takase H; Sugita S; Mochizuki M
Jpn J Ophthalmol; 2014 Jan; 58(1):75-80. PubMed ID: 24129677
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of infliximab therapy in active behcet's uveitis: an open-label trial.
Al-Rayes H; Al-Swailem R; Al-Balawi M; Al-Dohayan N; Al-Zaidi S; Tariq M
Rheumatol Int; 2008 Nov; 29(1):53-7. PubMed ID: 18496694
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
4. Clinical background comparison of patients with and without ocular inflammatory attacks after initiation of infliximab therapy.
Yoshida A; Kaburaki T; Okinaga K; Takamoto M; Kawashima H; Fujino Y
Jpn J Ophthalmol; 2012 Nov; 56(6):536-43. PubMed ID: 23053631
[TBL] [Abstract][Full Text] [Related]
5. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
6. Infliximab monotherapy versus infliximab and colchicine combination therapy in patients with Behçet's disease.
Takeuchi M; Asukata Y; Kawagoe T; Ito N; Nishide T; Mizuki N
Ocul Immunol Inflamm; 2012 Jun; 20(3):193-7. PubMed ID: 22486264
[TBL] [Abstract][Full Text] [Related]
7. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.
Keino H; Okada AA; Watanabe T; Taki W
Eye (Lond); 2014 Sep; 28(9):1100-6. PubMed ID: 24946845
[TBL] [Abstract][Full Text] [Related]
9. Long-term remission of ocular and extraocular manifestations in Behçet's disease using infliximab.
Handa T; Tsunekawa H; Yoneda M; Watanabe D; Mukai T; Yamamura M; Iwaki M; Zako M
Clin Exp Rheumatol; 2011; 29(4 Suppl 67):S58-63. PubMed ID: 21968238
[TBL] [Abstract][Full Text] [Related]
10. Behçet's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab.
Kaburaki T; Namba K; Sonoda KH; Kezuka T; Keino H; Fukuhara T; Kamoi K; Nakai K; Mizuki N; Ohguro N;
Jpn J Ophthalmol; 2014 Mar; 58(2):120-30. PubMed ID: 24482146
[TBL] [Abstract][Full Text] [Related]
11. Effects of infliximab in the treatment of refractory posterior uveitis of Behçet's disease after withdrawal of infusions.
Adán A; Hernandez V; Ortiz S; Molina JJ; Pelegrin L; Espinosa G; Sanmartí R
Int Ophthalmol; 2010 Oct; 30(5):577-81. PubMed ID: 20490893
[TBL] [Abstract][Full Text] [Related]
12. Anti-TNF-alpha therapy for sight threatening uveitis.
Lindstedt EW; Baarsma GS; Kuijpers RW; van Hagen PM
Br J Ophthalmol; 2005 May; 89(5):533-6. PubMed ID: 15834077
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial.
Tugal-Tutkun I; Mudun A; Urgancioglu M; Kamali S; Kasapoglu E; Inanc M; Gül A
Arthritis Rheum; 2005 Aug; 52(8):2478-84. PubMed ID: 16052571
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet's disease: a 24-month follow-up study.
Niccoli L; Nannini C; Benucci M; Chindamo D; Cassarà E; Salvarani C; Cimino L; Gini G; Lenzetti I; Cantini F
Rheumatology (Oxford); 2007 Jul; 46(7):1161-4. PubMed ID: 17478466
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features of patients with Behcet's uveitis].
Liu XS; Gao F; Zhao C; Zhang MF
Zhonghua Yan Ke Za Zhi; 2020 Mar; 56(3):217-223. PubMed ID: 32187951
[No Abstract] [Full Text] [Related]
16. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.
Keino H; Okada AA; Watanabe T; Taki W
Br J Ophthalmol; 2011 Sep; 95(9):1245-50. PubMed ID: 21183514
[TBL] [Abstract][Full Text] [Related]
17. Health- and vision-related quality of life in patients receiving infliximab therapy for Behcet uveitis.
Sakai T; Watanabe H; Kuroyanagi K; Akiyama G; Okano K; Kohno H; Tsuneoka H
Br J Ophthalmol; 2013 Mar; 97(3):338-42. PubMed ID: 23314623
[TBL] [Abstract][Full Text] [Related]
18. Clinical Follow-up of Patients with Behçet Uveitis after Discontinuation of Infliximab Therapy.
Köse HC; Yalçındağ N
Ocul Immunol Inflamm; 2022 Jan; 30(1):203-207. PubMed ID: 32779960
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.
Abu El-Asrar AM; Abboud EB; Aldibhi H; Al-Arfaj A
Int Ophthalmol; 2005 Jun; 26(3):83-92. PubMed ID: 17031510
[TBL] [Abstract][Full Text] [Related]
20. [Effects and safety of infliximab administration in refractory uveoretinitis with Behçet's disease].
Tanaka H; Sugita S; Yamada Y; Kawaguchi T; Iwanaga Y; Kamoi K; Yokota M; Takase H; Mochizuki M
Nippon Ganka Gakkai Zasshi; 2010 Feb; 114(2):87-95. PubMed ID: 20187505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]